ClinicalTrials.gg
RecruitingNCT07299448Updated Dec 23, 2025

Biological Determinants and Neural Compensation of Dysphagia in Parkinson's Disease

An observational study in Parkinsons Disease (PD) and Oropharyngeal Dysphagia, sponsored by Heinrich-Heine University, Duesseldorf. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Heinrich-Heine University, Duesseldorf · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 264 studies in Parkinson Disease with a site in Germany — 41 open to participants now, 53 under way, 2 of them phase 3. Parkinson Disease · Germany.

Planned enrollment
42nd of 64
100 · median 195
Started
2025
with 11 others
Observational
64 of 264
19 open now
Primary completion
2027-09
later than 29 of 52 live
Registered
254th of 264
by date

Among the 264 studies in Parkinson Disease with a site in Germany, this one is the 42nd largest by planned enrollment of the 64 observational ones that give a count, is one of 12 that started in 2025, is one of 64 observational ones, reaches primary completion later than 29 of the 52 other live ones, and was the 254th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

41 of the 264 studies in Parkinson Disease with a site in Germany are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 264 studies in Parkinson Disease with a site in Germany, or all of them as a file.
02

Study summary

Parkinson's disease (PD) is the second most common neurodegenerative disorder and frequently leads to oropharyngeal dysphagia, a swallowing disorder that strongly affects patient health and quality of life. Dysphagia in PD is associated with aspiration pneumonia, malnutrition, and impaired medication intake, which together represent one of the leading causes of morbidity and premature mortality in these patients. Despite its clinical relevance, the underlying biological mechanisms of dysphagia in PD are not fully understood, and current treatment strategies are limited.

The purpose of this study is to investigate the clinical, biological, and neural determinants of oropharyngeal dysphagia in patients with PD, and to explore compensatory mechanisms of the brain that may counteract swallowing difficulties. We hypothesize that dysphagia in PD is linked not only to disease severity and progression but also to specific biological markers and neural plasticity in the swallowing network.

This is a prospective, cross-sectional observational study including 100 patients with PD. Swallowing function will be systematically assessed using flexible endoscopic evaluation of swallowing (FEES), a gold standard method for detecting penetration and aspiration. Additional clinical data will be collected, including motor and non-motor symptoms, disease severity, and quality of life measures. Biological assessments will include blood-based biomarkers related to inflammation and neurodegeneration. Furthermore, functional magnetic resonance imaging (fMRI) will be used to examine cortical and subcortical activity patterns associated with swallowing and to identify potential compensatory activation in dysphagic and non-dysphagic patients.

By integrating clinical, biological, and imaging approaches, this study aims to provide a comprehensive characterization of dysphagia in PD. The findings are expected to improve the understanding of disease mechanisms and to identify predictors of dysphagia onset and severity. Ultimately, this knowledge may help to guide the development of targeted therapeutic strategies, reduce the risk of severe complications, and improve quality of life for patients with Parkinson's disease.

Read the detailed description

Background and Rationale Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide and is characterized by progressive motor and non-motor symptoms. Among its complications, oropharyngeal dysphagia (OD) is one of the most clinically relevant. Up to 80% of patients develop swallowing impairment during the course of the disease, often without recognizing its presence. Dysphagia is associated with aspiration pneumonia, malnutrition, dehydration, and impaired medication intake, representing a leading cause of morbidity and premature mortality in PD. Despite its high prevalence and impact, the underlying mechanisms of PD-related dysphagia are not fully understood, and current treatment options are limited.

Dysphagia in PD appears to be caused by a combination of central and peripheral factors. On the central level, dopamine deficiency contributes to motor dysfunction, including bradykinesia or freezing of swallowing. Cortical involvement and impaired sensorimotor integration may further reduce swallowing efficiency. On the peripheral level, impaired pharyngeal sensory function and reduced secretion of Substance P have been linked to silent aspiration and insufficient protective reflexes. Evidence from aging research and initial PD studies suggests that compensatory neural activity in cortical swallowing networks may mitigate the risk of aspiration in some patients. However, the clinical, biological, and neural determinants of preserved swallowing function and compensation in PD remain poorly defined.

Objectives and Hypotheses

The overarching objective of this study is to identify biological determinants and neural compensatory mechanisms of oropharyngeal dysphagia in PD. The specific aims are:

To characterize the prevalence, severity, and clinical phenotype of dysphagia in PD using standardized instrumental diagnostics.

To investigate biological determinants of swallowing impairment, including inflammatory and neurodegenerative markers in blood and saliva, sensory function, and proteomic signatures.

To examine neural correlates of swallowing function using task-based and resting-state functional magnetic resonance imaging (fMRI), diffusion tensor imaging (DTI), and muscle volumetry.

To identify clinical and biological factors associated with preserved neural compensation in PD, which may serve as potential therapeutic targets.

We hypothesize that dysphagia in PD is linked not only to disease progression but also to distinct biological markers and altered neural activity patterns. We further hypothesize that compensatory neural activation can be demonstrated in patients with mild dysphagia and that these mechanisms are modulated by clinical and biological determinants.

Study Design This is a prospective, cross-sectional observational study conducted at Heinrich-Heine-University Düsseldorf. A total of 100 patients with idiopathic PD across different disease stages will be recruited. The inclusion criterion is the ability to eat and drink orally and comply with study procedures. Exclusion criteria are tube feeding, other neurological or structural causes of dysphagia, severe comorbidities, or contraindications to MRI.

All participants will undergo a standardized study protocol consisting of three examination blocks:

Clinical and Instrumental Swallowing Assessment Swallowing will be assessed using Flexible Endoscopic Evaluation of Swallowing (FEES), which is considered a gold standard for detecting penetration, aspiration, and pharyngeal residue. The FEES protocol will include assessment of secretion management, swallowing of different consistencies, medication swallowing, dual-task swallowing (cognitive and motor load), pharyngeal sensitivity testing, and reflexive cough testing. Dysphagia severity and phenotype will be classified using validated scales.

Clinical, Biological, and Functional Assessments Clinical data will include demographics, disease duration, Hoehn \& Yahr staging, motor severity (UPDRS), non-motor symptoms, cognitive testing, frailty, sarcopenia, nutritional status, hydration, immunosenescence, and quality of life measures. Biological samples (saliva and blood) will be collected for biomarker analysis, including Substance P, inflammatory cytokines, and proteomic profiling. Smell and taste testing will be performed to assess sensory function.

Neuroimaging All participants will undergo MRI scanning, including structural MRI, diffusion tensor imaging, muscle volumetry, and functional MRI during swallowing and sensory stimulation tasks. Task-based fMRI will examine cortical and subcortical swallowing networks, dual-task swallowing under cognitive or motor load, and pharyngeal sensory stimulation. Resting-state fMRI will be used to investigate functional connectivity. DTI will assess white matter integrity in swallowing-related pathways.

Outcome Measures The primary outcome is the presence and severity of dysphagia as determined by FEES.

Secondary outcomes include:

Biological markers associated with dysphagia severity. fMRI activation patterns reflecting neural compensation. Relationships between clinical phenotype, biomarkers, and imaging findings. Identification of predictors of preserved swallowing function.

Expected Impact This study will provide a comprehensive, multimodal characterization of oropharyngeal dysphagia in PD by integrating clinical, biological, and neuroimaging data. It will improve the understanding of disease mechanisms, identify predictors of dysphagia onset and severity, and shed light on neural compensatory mechanisms. Ultimately, the findings are expected to guide the development of targeted therapeutic strategies, support earlier diagnosis, and improve patient care. In the long term, the study may contribute to reducing complications such as aspiration pneumonia and malnutrition, improving quality of life, and lowering the healthcare burden associated with PD-related dysphagia.

03

Conditions studied

  • Parkinsons Disease (PD)
  • Oropharyngeal Dysphagia

Keywords

  • Dysphagia, Swallowing Disorder, Parkinson's Disease, Swallowing Compensation, Neuroimaging Biomarkers, Functional MRI, Proteomics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of patients diagnosed with idiopathic Parkinson's disease according to the MDS diagnostic criteria (Postuma et al., 2015). Participants may be included in any stage of the disease, provided they are cognitively able to follow the study paradigm and are able to take food and liquids orally. Patients with exclusive tube feeding, comorbid conditions associated with oropharyngeal dysphagia (e.g., stroke, head and neck cancer, neuromuscular disorders), contraindications for MRI, or chronic pulmonary diseases such as asthma or COPD are excluded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

.- Patients with idiopathic Parkinson's disease diagnosed according to the MDS diagnostic criteria

  • Participation possible in all disease stages, regardless of the presence or absence of subjective or objective oropharyngeal dysphagia
  • Cognitive ability sufficient to comply with the study paradigm
  • Daily oral intake of food and fluids (exclusion of patients with exclusive tube feeding)

Exclusion criteria

Exclusion Criteria:

  • Presence of other conditions associated with oropharyngeal dysphagia, such as stroke, head and neck cancer, neuroinflammatory diseases, neuromuscular disorders, or other brain injuries
  • Presence of electronic stimulation devices (e.g., pacemaker, deep brain stimulation) or other for MRI imaging
  • Diagnosis of asthma or (due to performance of the cough reflex test in "Block 1: Assessment of OD and pharyngeal hyposensitivity")
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Parkinson's Disease Patients with Dysphagia

    Participants who have been diagnosed with Parkinson's disease and are still able to eat and drink independently. These individuals undergo a detailed examination of their swallowing function, compensatory mechanisms, and the neural correlates of dysphagia.

06

What researchers measure

Primary outcomes

  1. Dysphagia Severity assessed by Dynamic Imaging Grade of Swallowing Toxicity-Fiberoptic Endoscopic Evaluation of Swallowing (DIGEST-FEES)

    Swallowing safety and efficiency will be assessed using the Dynamic Imaging Grade of Swallowing Toxicity-Fiberoptic Endoscopic Evaluation of Swallowing (DIGEST-FEES). The DIGEST-FEES is a validated, ordinal rating scale that integrates measures of airway invasion (penetration-aspiration) and pharyngeal residue to generate a composite severity grade of dysphagia. Scores range from 0 (no dysphagia) to 4 (life-threatening dysphagia), with higher scores indicating greater swallowing impairment.

    Time frame: Baseline

Secondary outcomes

  1. Neural Activation Patterns (fMRI)

    Functional brain activity during swallowing tasks will be assessed using fMRI. Focus is on compensatory activation patterns in cortical and subcortical areas associated with swallowing control.

    Time frame: Baseline

  2. Electromyography (EMG) of Swallowing Muscles

    Surface EMG recordings will assess the number of swallows during fMRI

    Time frame: Baseline

  3. Change in Global Cognitive Function as Assessed by the Montreal Cognitive Assessment (MoCA)

    Global cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA), a validated, brief screening tool designed to detect mild cognitive impairment and broader cognitive dysfunction. The MoCA evaluates multiple cognitive domains, including: Attention and concentration Executive functioning Memory Language Visuospatial skills Abstraction Orientation Total scores range from 0 to 30, with higher scores indicating better cognitive performance. A change in MoCA score over time will be used to assess change in overall cognitive function.

    Time frame: Baseline

  4. Change in Swallowing-Related Quality of Life as Assessed by the Swallowing Quality of Life Questionnaire (SWAL-QOL)

    Swallowing-related quality of life will be assessed using the Swallowing Quality of Life Questionnaire (SWAL-QOL), a validated, patient-reported outcome measure designed specifically to evaluate the impact of dysphagia on daily functioning and well-being. The SWAL-QOL consists of 44 items across multiple domains, including: Burden Eating duration Eating desire Food selection Communication Fear Mental health Social functioning Fatigue Sleep Item responses are converted to domain and total scores typically scaled from 0 to 100, with higher scores indicating better swallowing-related quality of life. Change in SWAL-QOL total score (and/or domain scores) over time will be used to assess patient-perceived treatment effect.

    Time frame: Baseline

  5. Change in Airway Invasion Severity as Assessed by the Penetration-Aspiration Scale (PAS)

    Airway invasion during swallowing will be assessed using the Penetration-Aspiration Scale (PAS), an 8-point, validated, ordinal scale that quantifies the depth of bolus entry into the airway and the individual's response to that invasion during instrumental swallowing assessment. Scores range from 1 to 8, where: 1 = Material does not enter the airway 2-5 = Penetration (material enters the airway but remains above the vocal folds) 6-8 = Aspiration (material passes below the vocal folds), with higher scores indicating more severe impairment and reduced protective response Higher PAS scores indicate greater severity of airway compromise and increased aspiration risk.

    Time frame: Baseline

  6. Change in Pharyngeal Residue Severity as Assessed by the Yale Residue Severity Scale (YRSS)

    Pharyngeal residue following swallowing will be assessed using the Yale Residue Severity Scale (YRSS), a validated, ordinal rating scale designed for use with Fiberoptic Endoscopic Evaluation of Swallowing (FEES). The YRSS quantifies the amount of post-swallow residue within two key anatomical locations: Valleculae Pyriform sinuses Each site is scored separately on a 5-point scale: 0 = No residue 1. = Trace residue 2. = Mild residue 3. = Moderate residue 4. = Severe residue (nearly full or full pooling) Higher scores indicate greater impairment in swallowing efficiency and increased risk for post-swallow airway invasion.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — demographic data, clinical description of the cohort, and results of the examinations

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: beginning of recruitment until end of study

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.

Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 24 months is below that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2025
First posted
Dec 23, 2025
StartActual
Sep 1, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Jan 2028
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07299448
Collaborators
German Research Foundation
Responsible party
Sponsor
First posted
Dec 23, 2025
Start date
Sep 1, 2025
Primary completion
Sep 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Dec 23, 2025

Study contacts

Bendix Labeit
Contact
Bendix.Labeit@med.uni-duesseldorf.de
0049211811887

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion